Capricor Therapeutics (CAPR) shares were down more than 11% in recent trading on Monday after the company said the US Food and Drug Administration plans to hold an advisory committee meeting to review its biologics license application for deramiocel, an investigational cell therapy for treating cardiomyopathy in Duchenne muscular dystrophy patients.
Capricor said no significant deficiencies were identified in the application during a recent mid-cycle review meeting with the FDA. The agency is expected to decide by the Aug. 31 Prescription Drug User Fee Act target action date.
An official date for the advisory committee meeting has not yet been set, according to Capricor.
Price: 10.54, Change: -1.32, Percent Change: -11.13
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.